NASDAQ:CALA - Calithera Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.17 +0.02 (+0.39 %)
(As of 11/16/2018 04:00 PM ET)
Previous Close$5.17
Today's Range$5.07 - $5.33
52-Week Range$4.05 - $11.25
Volume157,828 shs
Average Volume425,116 shs
Market Capitalization$188.34 million
P/E Ratio-6.15
Dividend YieldN/A
Beta2.35
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
Previous Symbol
CUSIPN/A
Phone650-870-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio13.66
Quick Ratio13.66

Price-To-Earnings

Trailing P/E Ratio-6.15
Forward P/E Ratio-3.54
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.95 million
Price / Sales7.60
Cash FlowN/A
Price / CashN/A
Book Value$3.56 per share
Price / Book1.45

Profitability

EPS (Most Recent Fiscal Year)($0.84)
Net Income$-27,820,000.00
Net Margins-90.65%
Return on Equity-31.73%
Return on Assets-27.21%

Miscellaneous

Employees73
Outstanding Shares38,130,000
Market Cap$188.34 million
OptionableOptionable

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) issued its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.12. Calithera Biosciences had a negative return on equity of 31.73% and a negative net margin of 90.65%. View Calithera Biosciences' Earnings History.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Calithera Biosciences.

What price target have analysts set for CALA?

2 brokers have issued twelve-month target prices for Calithera Biosciences' stock. Their predictions range from $14.00 to $14.00. On average, they anticipate Calithera Biosciences' stock price to reach $14.00 in the next year. This suggests a possible upside of 170.8% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.

What is the consensus analysts' recommendation for Calithera Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.

Has Calithera Biosciences been receiving favorable news coverage?

Press coverage about CALA stock has trended neutral on Saturday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Calithera Biosciences earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Calithera Biosciences' key competitors?

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 64)
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 44)
  • Dr. Keith Orford, Sr. VP of Clinical Devel. (Age 46)
  • Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 44)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (2.59%), Man Group plc (1.96%), JPMorgan Chase & Co. (0.63%), JPMorgan Chase & Co. (0.59%), Prudential Financial Inc. (0.41%) and TIAA CREF Investment Management LLC (0.20%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., Renaissance Technologies LLC, Man Group plc, Bridgeway Capital Management Inc., Prudential Financial Inc., AQR Capital Management LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Calithera Biosciences.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, JPMorgan Chase & Co., JPMorgan Chase & Co. and Alps Advisors Inc.. View Insider Buying and Selling for Calithera Biosciences.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $5.17.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $188.34 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is http://www.calithera.com.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]


MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  398
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by MarketBeat.com Staff

Featured Article: Stop Order

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel